MedTrace Logo

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT07249905 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma

Conditions

Interventions

DRUG

MDX2003

MDX2003 intravenous infusion

Sponsors & Collaborators

  • ModeX Therapeutics, An OPKO Health Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-13
Primary Completion
2028-01-31
Completion
2030-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07249905 on ClinicalTrials.gov